Finder Award
SoFi Invest
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Entrada Therapeutics stock
Learn how to easily invest in Entrada Therapeutics stock.
Entrada Therapeutics is a biotechnology business based in the US. Entrada Therapeutics shares (TRDA) are listed on the NASDAQ and all prices are listed in US Dollars. Entrada Therapeutics employs 130 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy Entrada Therapeutics stock
- Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – TRDA. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Finder Award
Finder Award
eToro
- Easy to use platform with $0 stock trading & no annual fees
- Social trading allows you to copy popular portfolios
- FINDER EXCLUSIVE: Guaranteed $15 bonus when you sign up and deposit $100
tastytrade
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $100 - $2,000 when you open and fund an account with $5,000 to $100,000+
Entrada Therapeutics stock price (NASDAQ: TRDA)
Use our graph to track the performance of TRDA stocks over time.Entrada Therapeutics shares at a glance
Information last updated 2023-03-24.
| Latest market close | $14.77 |
|---|---|
| 52-week range | $5.12 - $24.38 |
| 50-day moving average | $13.09 |
| 200-day moving average | $14.12 |
| Wall St. target price | $18.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-4.08 |
Buy Entrada Therapeutics stocks from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.1 - 6 of 6
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Is it a good time to buy Entrada Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Entrada Therapeutics price performance over time
Historical closes compared with the close of $14.77 from 2023-03-29
| 1 week (2023-03-23) | -8.83% |
|---|---|
| 1 month (2023-03-02) | 45.52% |
| 3 months (2022-12-30) | 9.25% |
| 6 months (2022-09-30) | -6.28% |
| 1 year (2022-03-30) | 54.66% |
|---|---|
| 2 years (2021-03-26) | N/A |
| 3 years (2020-03-26) | N/A |
| 5 years (2018-03-26) | N/A |
Entrada Therapeutics financials
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -21.79% |
| Return on equity TTM | -37.01% |
| Profit margin | 0% |
| Book value | $6.77 |
| Market capitalisation | $535.8 million |
TTM: trailing 12 months
Entrada Therapeutics share dividends
We're not expecting Entrada Therapeutics to pay a dividend over the next 12 months.
Entrada Therapeutics overview
Entrada Therapeutics, Inc. , a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead therapeutic candidates, which include ENTR-601-44 and ENTR-601-45, which are in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1; ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy; and ENTR-701, which is in preclinical trail for the treatment of myotonic dystrophy type 1. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc.
Entrada Therapeutics in the news
Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference
5AM Ventures Celebrates 20th FDA Product Approval Investing in Breakthrough Science
Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
Frequently asked questions
What percentage of Entrada Therapeutics is owned by insiders or institutions?Currently 16.139% of Entrada Therapeutics shares are held by insiders and 74.87% by institutions. How many people work for Entrada Therapeutics?
Latest data suggests 130 work at Entrada Therapeutics. When does the fiscal year end for Entrada Therapeutics?
Entrada Therapeutics's fiscal year ends in December. Where is Entrada Therapeutics based?
Entrada Therapeutics's address is: 6 Tide Street, Boston, MA, United States, 02210 What is Entrada Therapeutics's ISIN number?
Entrada Therapeutics's international securities identification number is: US29384C1080
More guides on Finder
-
What happens if a brokerage firm fails?
Here’s what happens to your securities if your brokerage fails, and how your assets are protected by SIPC and FDIC.
-
How to Buy Gold Stocks
Learn about buying physical gold, plus stocks and ETFs, to learn how you can add gold exposure to your portfolio.
-
Silicon Valley Bank collapse: Which ETFs and stocks are impacted?
Several ETFs have exposure to Silicon Valley Bank, but it appears minimal.
-
How to Buy Treasury Bills
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
-
SVB collapses: What does it mean for your portfolio?
The 16th largest US bank has collapsed, but its impact on your portfolio could be limited depending on what you own.
-
How to buy Vanguard VTI Total Stock Market ETF units
Steps to investing in the Vanguard (VTI) Total Stock Market ETF.
-
How to buy Neuraxis (NRXS) stock when it goes public
Everything we know about the Neuraxis IPO, plus information on how to buy in.
-
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
-
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
-
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
Ask an Expert